Multifunctional integrated central venous catheter

By using anticoagulant high-pressure polyurethane material and multidirectional valve structure, combined with bidirectional subcutaneous anchor fixation device and monitoring guidewire, the problem of prone to rupture and thrombosis under high pressure is solved, and the stability of the catheter is achieved and Improved safety, and real-time monitoring of central venous pressure and ECG signals.

WO2024251180A1PCT designated stage expired Publication Date: 2024-12-12SHANDONG BRANDEN MEDICAL DEVICE
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/097646
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-07
Filing Date
2024-06-06
Publication Date
2024-12-12

AI Technical Summary

Technical Problem

Traditional central venous catheters are prone to swelling, deformation, rupture and leakage under high pressure, and cannot effectively prevent thrombosis and blood reflux, lack monitoring functions, affecting the treatment effect and safety.

Method used

A multi-directional valve central venous catheter made of anticoagulant high-pressure polyurethane material combines a bidirectional subcutaneous anchor fixing device and monitoring guidewire to achieve the high-pressure stability, anticoagulation, anti-thrombosis and real-time monitoring functions of the catheter.

Benefits of technology

It improves the high-pressure and anticoagulation performance of the catheter, reduces the risks of thrombosis and ectopic shedding, realizes real-time monitoring of central venous pressure and ECG signals, and enhances the stability and safety of the catheter.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024097646_12122024_PF_FP_ABST
    Figure CN2024097646_12122024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed in the present invention is a multifunctional integrated central venous catheter. The catheter has the following characteristics: 1) the catheter body is prepared from an anticoagulant and high-pressure-resistant polyurethane to achieve the double functions of high-pressure resistance and three-way valve at the end; 2) a bidirectional subcutaneous anchor securement device is arranged to prevent catheter malposition and falling-off; and 3) a monitoring guide wire is arranged to realize the real-time monitoring of electrocardiogram signals, the closing of valves and central venous pressure. The central venous catheter of the present invention has the functions of high-pressure resistance, anticoagulation, and malposition and falling-off prevention, and can be used for monitoring electrocardiogram signals and central venous pressure, and the using effect and safety of the central venous catheter are improved.
Need to check novelty before this filing date? Find Prior Art

Description

A multifunctional integrated central venous catheter Technical Field

[0001] The invention relates to a multifunctional integrated high-pressure-resistant multi-directional valve-type central venous catheter, belonging to the field of medical equipment. Background Art

[0002] Central venous catheterization is a widely used medical technique that can provide patients with continuous intravenous drug infusion, nutritional support, and other medical treatments. It is widely used in clinical practice due to its ease of operation and high safety. However, traditional central venous catheters have some important drawbacks in use, such as:

[0003] 1. During enhanced CT scanning, intravenous injection of contrast agents requires high flow rate, high pressure, and large dose. Traditional catheters are prone to swelling, deformation, rupture, and leakage under high pressure, thus affecting their effectiveness.

[0004] 2. After the catheter is placed, it is usually necessary to fix the tube to the patient's body with medical tape or sterile film to prevent the tube from falling off or shifting. During the long-term catheterization process, if the fixation is improper or the patient's limbs move, the catheter may become dislocated or the tube may be removed;

[0005] 3. The placement of a central venous catheter can lead to coagulation complications, easily forming blood clots, which may cause blockage of the pipeline and affect the treatment effect. If the blood clot breaks off, it will flow with the blood to other parts of the body, causing local tissue ischemia, hypoxia, and necrosis. In severe cases, it may even cause life-threatening complications such as pulmonary embolism.

[0006] Multidirectional valved central venous catheters effectively avoid the risks of air embolism and blood reflux-induced coagulation, offering a low incidence of tube blockage. However, this design typically cannot be combined with high-pressure resistance. This is because high-pressure PICC catheters are typically made from materials with high strength to ensure suitability for high-pressure environments. However, this high-strength material reduces flexibility, making it impossible to achieve a multidirectional valve. Therefore, achieving both a multidirectional valve and high-pressure resistance is a significant challenge for PICC catheter materials.

[0007] In addition, monitoring blood pressure and electrocardiogram (ECG) signals is also a very important task during central venous catheterization. However, traditional central venous catheters lack this monitoring function and cannot provide accurate and timely monitoring.

[0008] CN116036448A discloses a central venous catheter (CVC) for preventing thrombosis. The device includes a CVC and a blocking device. This device completely flushes blood from the CVC back into the blood vessel and completely blocks the CVC's opening to prevent blood from flowing back into the CVC. However, this device primarily addresses blood coagulation and blockage within the catheter, and does not address thrombosis caused by protein and blood cell deposition outside the catheter.

[0009] CN211068620U discloses a disposable sterile peripherally inserted central venous catheter, comprising an implantable body, an extension tube, and a connector. A control valve pad is located within the connector, equipped with positive and negative pressure valves. These control valves control forward flow, side hole backflow, and balance of fluid flow. However, the control valve is primarily made of silicone, which has low mechanical strength and is unsuitable for high-pressure injections, prone to rupture and deformation.

[0010] At present, how central venous catheters can achieve the dual functions of high pressure resistance and multi-directional valves has not yet been solved. Anticoagulation and monitoring functions are also the general direction of central venous catheter improvement, but a solution that can include the above functions has not yet been found, and further research and development is needed.

[0011] Summary of the Invention

[0012] In order to solve the above problems, the present invention proposes a high-pressure-resistant, anti-coagulation multi-directional valve central venous catheter. The polyurethane material used has excellent mechanical properties, which can meet the requirements of high-pressure injection of the catheter. In addition, it also has an anti-coagulation effect. The catheter is prepared by integrating two polyurethanes with different mechanical properties, which can simultaneously achieve high-pressure resistance and multi-directional valve functions. The catheter can monitor electrocardiogram signals, valve closure status and central venous pressure in real time by inserting a monitoring guide wire.

[0013] The central venous catheter of this invention has a dual-lumen structure: one lumen is used for drug infusion and blood withdrawal, and the other is used to monitor central venous pressure and electrocardiogram signals. The catheter body is equipped with a bidirectional subcutaneous anchor fixation device, which effectively secures the catheter and prevents it from shifting or falling out during use due to patient movement or coughing. This anchor fixation device improves the effectiveness and safety of central venous catheters, reducing unnecessary burdens on doctors and patients.

[0014] The present invention solves the shortcomings mentioned in the above background technology by providing a multi-directional valve central venous catheter, which gives the central venous catheter the functions of high pressure resistance, anti-coagulation, anti-misplacement and anti-falloff, and the ability to monitor central venous pressure and electrocardiogram signals.

[0015] The present invention provides a multifunctional integrated central venous catheter, which adopts the following technical solutions:

[0016] A multifunctional, integrated central venous catheter (CVC) is constructed from anticoagulant, high-pressure-resistant polyurethane. A multidirectional valve is installed at the distal end of the catheter. The catheter consists of a main section and a valve section, each with different material properties. The main section has a hardness of 78-92A, an elongation at break of ≥480%, a strain at 300% of 8.8-10.3 MPa, a tensile strength of 48-56 MPa, and a tear strength of ≥42 kN / m. The valve section has a hardness of 33-38A, an elongation at break of ≥723%, a strain at 300% of 1.7-2.2 MPa, a tensile strength of 17-22 MPa, and a tear strength of ≥27 kN / m. The main section is equipped with a bidirectional subcutaneous anchor device, which secures the catheter subcutaneously during placement. During use, the catheter can monitor ECG signals and central venous pressure in real time via a monitoring guidewire.

[0017] Furthermore, the preparation method of the anticoagulation high-pressure resistant polyurethane is:

[0018] (1) Preparation of heparinized cage oligomeric silsesquioxane (heparinized-POSS): Sodium heparin, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), and N-hydroxysuccinimide (NHS) were added to a round-bottom flask, and sodium citrate buffer solution with a pH of 4.8 was added to make the sodium heparin concentration 1 g / L. The mixture was reacted at 4°C for 24 hours. Octaamino cage oligomeric silsesquioxane (octaamino-POSS) was then dissolved in methanol at a concentration of 2 g / L and placed in a single-necked round-bottom flask. The mixture was reacted at 40°C for 24 hours. The mass ratio of sodium heparin, EDC, NHS, and octaamino-POSS was 3:3:3:2. After the reaction was completed, the mixture was fully shaken and washed at room temperature and dried in a vacuum drying oven.

[0019] (2) Preparation of main segment polyurethane by prepolymer method: under N2 protection, polybutylene adipate diol (PBA) was added to a dry three-necked flask equipped with a mechanical stirrer, and heated at 120°C for 2h under vacuum (<133Pa) to remove moisture. Isophorone diisocyanate (IPDI) and dibutyltin dilaurate (DBTDL) were added to the flask equipped with a stirrer, and prepolymerized at 80°C for 3h to obtain a prepolymer with an isocyanate terminal group. 1,4-Butanediol (BDO) was added and reacted at 60°C for 0.5h. The mixture was cooled to room temperature. The molar ratio of the added materials was IPDI:PBA:BDO=3:1:(1-1.2). The amount of DBTDL added was 0.05wt% of the total amount of the added materials.

[0020] (3) Functionalization of the main segment material: 5 wt% of tetrahydrofuran was added to the main segment polyurethane prepared in step (2) to reduce the viscosity, and the heparinized-POSS prepared in step (1) was added with a molar ratio of IPDI to heparinized-POSS of 1:0.05. The mixture was stirred at 60° C. for 1 h, then poured into a polytetrafluoroethylene mold, dried in a blast drying oven for 24 h, and then transferred to a vacuum drying oven for drying for 12 h to obtain a heparinized high-pressure resistant polyurethane elastomer material.

[0021] Furthermore, the valve segment material synthesis steps include: under N2 protection, PBA is added to a dry three-necked flask equipped with a mechanical stirrer. The mixture is heated at 120°C for 2 hours under vacuum (<133 Pa) to remove moisture. IPDI and DBTDL are then added to the stirrer flask and prepolymerized at 80°C for 3 hours to obtain a prepolymer. BDO is then added and reacted at 60°C for 2 hours. The heat is then turned off, and trimethylolpropane (TMP) is added. The mixture is stirred for 10 minutes and cooled to room temperature. The molar ratio of IPDI:PBA:BDO is 3:(0.5-0.8):(0.8-1). The DBTDL is added in an amount of 0.15 wt% of the total. The mixture is then poured into a polytetrafluoroethylene mold, dried in a forced air oven for 24 hours, and then transferred to a vacuum oven for 12 hours to obtain a high-pressure resistant polyurethane elastomer material for the valve segment.

[0022] Furthermore, the main body section is provided with a bidirectional subcutaneous anchor fixing device, which includes left and right sides, which can completely overlap. The outer surface of the device is ellipsoidal as a whole, and there are uniform gear-shaped notches, which are 45 degrees to the tube body. The middle of the device is a hollow structure, and the edges of the device (i.e., both ends) are connected to the catheter. The left and right devices are on the same horizontal line, and the left and right devices are centrally symmetrical with the intersection of the catheter axis and the horizontal line as the center point. The notches on both sides are 180 degrees, that is, the notches on both sides are centrally symmetrical. When the catheter is placed, the anchor part is placed in the subcutaneous tissue of the puncture point, and is fixed in both directions in the subcutaneous tissue through the bidirectional notches, thereby preventing the catheter from being dislocated and falling off. When inserting and removing, external force is used to squeeze the hollow part into a depression, reducing the volume of the anchor point and preventing secondary damage to the skin tissue.

[0023] Preferably, the anchor fixing device is made of silicone rubber and / or polyurethane with a hardness of 40 to 60A, and is bonded to the catheter through a coupling agent.

[0024] Furthermore, the main body section of the central venous catheter has high hardness, which ensures the support of the catheter, and the valve section has low hardness, which ensures the withdrawal function of the valve.

[0025] Preferably, the length of the valve segment is 3 to 8 cm, for example, 3 cm, 4 cm, 5 cm, 6 cm, 7 cm, or 8 cm.

[0026] Preferably, the valve segment is joined to the main body segment by coupling agent bonding, welding or one-end injection molding.

[0027] Furthermore, this central venous catheter is a dual-lumen catheter, comprising a left lumen and a right lumen, which are two independent, disconnected lumens. Both the left and right lumen valve segments are equipped with multi-directional valves. The catheter tip is made of a conductive polyurethane material, doped with 5-10 wt% graphene oxide, and is 2-3 mm in length.

[0028] Furthermore, a monitoring guide wire can be inserted into the right lumen. The monitoring guide wire is made of metal and has a hollow structure in the center. It has an outer diameter of 0.3mm, an inner diameter of 0.15mm, and the diameter of the end is thickened to 0.4mm to form an ECG signal receiving end. The length is 0.5cm. After the catheterization is completed, the monitoring guide wire can continue to be inserted into the catheter. The ECG signal receiving end contacts the conductive head part, and the other end is exposed to the body through an extension tube and connected to a data receiving device. It can perform real-time monitoring of ECG signals and can be pulled out when not in use.

[0029] Furthermore, the hollow structure of the monitoring guidewire has a built-in optical fiber, and a circular hole is opened on one side of the ECG signal receiving end, which is connected to the hollow structure. A micro-electromechanical system (MEMS) Fabry-Perot cavity pressure sensor is embedded in the hole. The sensor is connected to the optical fiber, and the other end of the optical fiber extends out of an extension tube to connect to the optical fiber connector, which is connected to the data receiving equipment to form a pressure conduction path.

[0030] Preferably, the diameter of the optical fiber is ≤0.12 mm, the diameter of the MEMS Fabry-Perot cavity pressure sensor is 0.26 mm, the diameter of the circular hole is 0.28 mm, and the detection range is 0 to 500 mmHg.

[0031] Preferably, the monitoring guidewire is made of a metal or alloy with good conductivity and plasticity.

[0032] Preferably, the monitoring guide wire is one or more of silver-tungsten alloy, silver-copper alloy, and silver-iron alloy.

[0033] The present invention has the following technical effects:

[0034] 1. The invention provides an anticoagulant, high-pressure resistant polyurethane material: the larger physical volume of POSS can effectively hinder the motion of the polymer main chain, improve the thermal stability and mechanical property of the material. Use heparinized POSS modified polyurethane to obtain a polyurethane material with anticoagulant effect and excellent mechanical property. On the other hand, heparinized POSS is grafted on the polyurethane molecule by chemical bond, and the engagement of heparin, POSS and polyurethane is more stable, which can provide corresponding functions for a long time. The catheter made from this material can withstand a pressure of up to 350psi and is not prone to rupture and leakage during high-pressure injection, thereby ensuring the safety and stability of the catheter. Simultaneously, the good anticoagulant performance of the catheter can effectively prevent the formation of catheter blockage and intravascular thrombosis, reduce the generation of coagulant complications, and improve the service life and success rate of the catheter.

[0035] 2. The present invention provides, for the first time, a high-pressure-resistant central venous catheter with a multidirectional valve at the end. The valve segment of the catheter is made of a material with low hardness and a low elastic modulus, which increases the sensitivity of the multidirectional valve and enables negative pressure suction, positive pressure injection, and pressure-free sealing. Existing high-pressure-resistant central venous catheters cannot be directly equipped with a multidirectional valve structure on the catheter body due to their high hardness and low elasticity. The valve structure is usually connected to an extension tube through assembly. Although this can prevent blood from flowing back out of the body, it inevitably allows blood to enter the catheter body. The valve provided by the present invention is arranged at the end of the catheter body and implanted into the human body along with the catheter, effectively preventing blood from entering the catheter, thereby reducing thrombosis within the catheter.

[0036] 3. The present invention contains a monitoring guidewire that can simultaneously monitor the intra-tube pressure, central venous pressure and electrocardiogram signals. The guidewire monitors the intra-tube pressure in real time through a pressure sensor. When the pressure in the blood vessel and the catheter is balanced, the valve closes, and the monitored intra-tube pressure reflects the blood pressure in the vein. At the same time, the closed or not valve can be judged by the monitored pressure and its stability, thereby avoiding reflux and blood return caused by incorrect judgment of valve opening and closing; the catheter uses a conductive head, and a conductive path is formed by inserting the monitoring guidewire and connecting it with the head to monitor the electrocardiogram signals. The monitoring guidewire can be withdrawn when not in use; the catheter has a dual-lumen structure. While one cavity is normally performing drug infusion and blood withdrawal, the other side can monitor the intra-tube pressure, central venous pressure and electrocardiogram signals. All monitoring will not affect the normal use of the catheter, and monitoring can be done at any time.

[0037] 4. The bidirectional subcutaneous anchor fixation design is adopted. The device is placed subcutaneously, which can effectively fix the catheter in both directions, prevent the tube from shifting or falling off in the body, improve the stability and safety of the catheter, and also reduce the patient's pain and discomfort. The hollow structure can apply external force to form a depression when inserting and removing, reducing the volume of the device, thereby reducing secondary damage to the subcutaneous tissue.

[0038] In summary, the present invention is highly practical and innovative, providing a safer, more reliable and comfortable treatment method for patients who use central venous catheters for a long time, and has important significance and value for clinical treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Fig. 1 is the synthesis flow chart of heparinized POSS-polyurethane material;

[0040] FIG2 is a cross-sectional schematic diagram of a bidirectional subcutaneous anchor fixation device;

[0041] FIG3 is a top view of a bidirectional subcutaneous anchor fixation device;

[0042] FIG4 is a schematic diagram of a multifunctional integrated central venous catheter;

[0043] FIG5 is a schematic diagram of a cross section of a monitoring guide wire.

[0044] In the figure, a is the left lumen, b is the right lumen, 1 is the valve segment, 2 is the main body segment, 3 is the conductive head, 4 is the right lumen valve, 5 is the left lumen valve, 6 is the ECG signal receiving end, 7 is the monitoring guide wire, 8 is the bidirectional subcutaneous anchor fixing device, 9 is the fixing wing, 10 is the extension tube, 11 is the thumb clip, 12 is the data receiving device, 13 is the optical fiber, and 14 is the micro-electromechanical system Fabry-Perot cavity pressure sensor. DETAILED DESCRIPTION

[0045] The following is a clear and complete description of the technical solutions in the embodiments of the present invention. Obviously, the embodiments described are only some embodiments of the present invention, not all embodiments. All other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making any creative efforts are within the scope of protection of the present invention.

[0046] Unless otherwise specified, the reagents used in the examples of the present invention are common commercially available products.

[0047] The multifunctional integrated central venous catheter of the present invention is as follows:

[0048] A multifunctional integrated central venous catheter comprises a left lumen a, a right lumen b, a right lumen valve 4, a left lumen valve 5, a bidirectional subcutaneous anchor fixing device 8, a thumb clip 11, a fixing wing 9, a monitoring guide wire 7, a conductive head 3 and an extension tube 10.

[0049] As shown in Figure 4, the multifunctional integrated central venous catheter is a dual-lumen catheter, comprising a left lumen a and a right lumen b. The left lumen a is used for drug injection and blood withdrawal, while the right lumen b houses a removable monitoring guidewire 7. The bodies of both lumen a and b consist of a main body section 2 and a valve section 1. The valve sections are equipped with multidirectional valves, such as three-way valves. The main body section 2 and valve section 1 are interconnected within the left and right lumens a and b. The left and right lumens a and b are identical in shape and size and are not interconnected. A left luminal valve 5 is provided at the valve section 1 of the left lumen a, while a right luminal valve 4 is provided at the valve section 1 of the right lumen b. The right and left luminal valves 4 and 5 are of equal length, ranging from 0.5 to 0.8 cm, with incisions parallel to the body. The valve section 1 is 3 to 8 cm long and is joined to the main body section 2 by bonding with a coupling agent, welding, or one-end injection molding.

[0050] Furthermore, the main segment is prepared from an anti-coagulant, high-pressure resistant polyurethane material. The synthesis process of the material is as follows: isophorone diisocyanate and polybutylene adipate diol are used to synthesize a prepolymer, which is then chain extended via 1,4-butanediol to obtain a chain segment; heparin and cage-type oligomeric silsesquioxane are then chemically grafted to form a heparinized cage-type oligomeric silsesquioxane, and the synthesized chain segment is capped with the heparinized cage-type oligomeric silsesquioxane to produce the product.

[0051] Furthermore, the main body section is provided with a bidirectional subcutaneous anchor fixture 8, which is placed subcutaneously to secure the bidirectional catheter during catheterization. The bidirectional subcutaneous anchor fixture 8 includes left and right sides, which can completely overlap. As shown in FIG2 , after the left and right sides are installed, the outer surface of the fixture is generally ellipsoidal, with the width gradually decreasing from the center of the fixture to the two sides (i.e., the two ends). The length of the fixture is 0.5 to 1.0 cm, and the maximum width of the left and right sides is 0.3 to 0.5 cm. The outer surface of the device has uniform gear-shaped notches, which are at a 45° angle to the tube body of the multifunctional integrated central venous catheter. The center of the fixture is hollow, and the edges of the fixture (i.e., the two ends of the fixture) are connected to the multifunctional integrated central venous catheter. The left and right fixtures are on the same horizontal line and are centrally symmetrical about the intersection of the catheter axis and the horizontal line. The notches on the left and right sides are 180°, that is, the notches on the left and right sides are also centrally symmetrical about the intersection of the catheter axis and the horizontal line. When the left and right sides are merged together, the notches form elliptical rings on the outer surface of the fixing device; the bidirectional subcutaneous anchor fixing device 8 is made of silicone rubber and / or polyurethane with a hardness of 40 to 60A, and is bonded to the main body section 2 through a coupling agent.

[0052] Furthermore, the end of the monitoring guide wire is an ECG signal receiving end. When in use, the ECG signal receiving end is connected to the conductive head and connected to the data receiving device 12 through the monitoring guide wire; the center of the monitoring guide wire is a hollow structure with a built-in optical fiber 13, and the ECG signal receiving end is embedded with a micro-electromechanical system Fabry-Perot cavity pressure sensor 14, which is connected to the optical fiber. The other end of the optical fiber extends out of the tube and is connected to the optical fiber connector, which is connected to the data receiving device to form a pressure conduction path.

[0053] Furthermore, the catheter seal is a conductive seal. The conductive seal 3 is made of a conductive polyurethane material, which is formed by doping 5 to 10 wt% of graphene oxide on the basis of the polyurethane material used in the main section 2 . As shown in Figures 4 and 5, a monitoring guide wire 7 is built into the right lumen b. The monitoring guide wire 7 is made of metal, has a hollow structure in the center, an outer diameter of 0.3mm, an inner diameter of 0.15mm, and the end is thickened to a diameter of 0.4mm to form an ECG signal receiving end 6 with a length of 0.5cm. When in use, the ECG signal receiving end is connected to the conductive head and connected to the data receiving device 12 through the monitoring guide wire. An optical fiber 13 is built into the hollow structure with a diameter of ≤0.12mm. A circular hole with a diameter of 0.28mm is opened on one side of the ECG signal receiving end 6 and is connected to the hollow structure. A micro-electromechanical system Fabry-Perot cavity pressure sensor 14 with a diameter of 0.26mm is embedded in the hole. The micro-electromechanical system Fabry-Perot cavity pressure sensor 14 is connected to the optical fiber 13. The other end of the optical fiber 13 extends out of the extension tube 10 and is connected to the optical fiber connector, which is connected to the data receiving device 12 to form a pressure conduction path with a detection range of 0 to 500mmHg. The monitoring guide wire 7 is one or more of silver-tungsten alloy, silver-copper alloy, and silver-iron alloy.

[0054] The method for preparing the multifunctional integrated central venous catheter of the present invention comprises the following steps:

[0055] 1. The preparation method of the anti-coagulation and high-pressure resistant polyurethane of the main section 2 is as follows:

[0056] (1) Preparation of heparinized POSS: Sodium heparin, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), and N-hydroxysuccinimide (NHS) were added to a round-bottom flask, and sodium citrate buffer solution with a pH of 4.8 was added to make the sodium heparin concentration 1 g / L. The mixture was reacted at 4°C for 24 h. Then, octaamino cage-type oligomeric silsesquioxane (octaamino-POSS) dissolved in methanol at a concentration of 2 g / L was placed in a single-necked round-bottom flask and the reaction was continued at 40°C for 24 h. The mass ratio of sodium heparin, EDC, NHS, and octaamino-POSS was 3:3:3:2. After the reaction was completed, the mixture was fully shaken and washed at room temperature and dried in a vacuum drying oven.

[0057] (2) Preparation of polyurethane of main segment 2 by prepolymer method: under N2 protection, polybutylene adipate diol (PBA) was added to a dry three-necked flask equipped with a mechanical stirrer, and heated at 120°C for 2 h under vacuum (<133 Pa) to remove moisture. Isophorone diisocyanate (IPDI) and dibutyltin dilaurate (DBTDL) were added to the flask equipped with a stirrer, respectively, with the added molar ratio of IPDI:PBA:BDO=3:1:(1-1.2). The amount of DBTDL added was 0.05 wt% of the total amount of the added materials. The prepolymer was prepolymerized at 80°C for 3 h to obtain a prepolymer with an isocyanate terminal group. BDO was added and reacted at 60°C for 0.5 h, and then cooled to room temperature.

[0058] (3) Material functionalization of the main segment 2: 5 wt% of tetrahydrofuran was added to the polyurethane of the main segment 2 prepared in step (2) to reduce the viscosity, and the heparinized POSS prepared in step (1) was added with a molar ratio of IPDI to heparinized POSS of 1:0.05. The mixture was stirred at 60° C. for 1 h, then poured into a polytetrafluoroethylene mold, dried in a blast drying oven for 24 h, and then transferred to a vacuum drying oven for drying for 12 h to obtain a heparinized high-pressure resistant polyurethane elastomer material.

[0059] 2. The material synthesis method of the valve segment 1 is as follows:

[0060] Under nitrogen, polybutylene adipate diol (PBA) was added to a dry three-necked flask equipped with a mechanical stirrer. The mixture was heated at 120°C for 2 hours under vacuum (<133 Pa) to remove moisture. Isophorone diisocyanate (IPDI) and dibutyltin dilaurate (DBTDL) were then added to the stirrer flask and prepolymerized at 80°C for 3 hours to produce a prepolymer. BDO was then added and reacted at 60°C for 2 hours. The heat was then turned off, and trimethylolpropane (TMP) was added. The mixture was stirred for 10 minutes and cooled to room temperature. The molar ratio of IPDI:PBA:BDO was 3:(0.5-0.8):(0.8-1). The DBTDL was added in an amount of 0.15 wt% of the total. The mixture was then poured into a polytetrafluoroethylene mold, dried in a forced air oven for 24 hours, and then transferred to a vacuum oven for 12 hours to produce the high-pressure resistant polyurethane elastomer material for valve segment 1.

[0061] The hardness of the polyurethane material of the prepared main segment 2 is 78~92A, the elongation at break is ≥480%, the strain at 300% is 8.8~10.3MPa, the tensile strength is 48~56MPa, and the tear strength is ≥42kN / m; the hardness of the material of the prepared valve segment 1 is 33~38A, the elongation at break is ≥723%, the strain at 300% is 1.7~2.2MPa, the tensile strength is 17~22MPa, and the tear strength is ≥27kN / m.

[0062] Example 1

[0063] A multifunctional integrated central venous catheter is as follows:

[0064] 1. Preparation method of anti-coagulation and high-pressure resistant polyurethane of main section 2:

[0065] (1) Preparation of heparinized POSS: Take 0.03g of sodium heparin, 0.03g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), 0.03g of N-hydroxysuccinimide (NHS), and 30mL of sodium citrate buffer solution (pH=4.8) respectively, add them to a 100mL single-necked round-bottom flask, and react at 4℃ for 24h. Then dissolve 0.02g of octaamino cage-type oligomeric silsesquioxane (octaamino-POSS) in 10mL of methanol, and then put it into a single-necked round-bottom flask and continue to react at 40℃ for 24h. After the reaction is completed, shake and wash thoroughly at room temperature and dry in a vacuum drying oven;

[0066] (2) Preparation of polyurethane of main segment 2 by prepolymer method: under N2 protection, polybutylene adipate diol (PBA) was added to a dry three-necked flask equipped with a mechanical stirrer, and heated at 120°C for 2 h under vacuum (<133 Pa) to remove moisture. Isophorone diisocyanate (IPDI) and dibutyltin dilaurate (DBTDL) were added to the flask equipped with a stirrer, respectively, with a molar ratio of IPDI:PBA:BDO = 3:1:1.1. The amount of DBTDL added was 0.05 wt% of the total amount of the added materials. The mixture was prepolymerized at 80°C for 3 h to obtain a prepolymer with isocyanate end groups. BDO was added and reacted at 60°C for 0.5 h, and then cooled to room temperature.

[0067] (3) Material functionalization of the main segment 2: 5 wt% of tetrahydrofuran was added to the polyurethane of the main segment 2 prepared in step (2) to reduce the viscosity, and the heparinized POSS prepared in step (1) was added with a molar ratio of IPDI to POSS of 1:0.05. The mixture was stirred at 60° C. for 1 h, then poured into a polytetrafluoroethylene mold, dried in a blast drying oven for 24 h, and then transferred to a vacuum drying oven for drying for 12 h to obtain a heparinized high-pressure resistant polyurethane elastomer material.

[0068] 2. The material synthesis method of the valve segment 1 is as follows:

[0069] Under nitrogen protection, polybutylene adipate diol (PBA) was added to a dry three-necked flask equipped with a mechanical stirrer and heated at 120°C for 2 hours under vacuum (<133 Pa) to remove moisture. Isophorone diisocyanate (IPDI) and dibutyltin dilaurate (DBTDL) were separately added to the stirrer flask and prepolymerized at 80°C for 3 hours to obtain a prepolymer. BDO was added and reacted at 60°C for 2 hours. The heat was then turned off and trimethylolpropane (TMP) was added. The mixture was stirred for 10 minutes and cooled to room temperature. A molar ratio of IPDI:PBA:BDO was 3:0.7:0.9, and DBTDL was added in an amount of 0.15 wt% of the total. The mixture was then poured into a polytetrafluoroethylene mold, dried in a forced air drying oven for 24 hours, and then transferred to a vacuum drying oven for 12 hours to obtain the high-pressure resistant polyurethane elastomer material of valve segment 1.

[0070] 3. The structure of a multifunctional integrated central venous catheter is as follows:

[0071] A multifunctional integrated central venous catheter comprises a left lumen a, a right lumen b, a right lumen valve 4, a left lumen valve 5, a bidirectional subcutaneous anchor fixing device 8, a thumb clip 11, a fixing wing 9, a monitoring guide wire 7, a conductive head 3 and an extension tube 10.

[0072] This catheter has a dual-lumen structure, including a left lumen a and a right lumen b. Both lumen a and b consist of a main body section 2 and a valve section 1. The main body section 2 and valve section 1 are interconnected, leaving the left and right lumens a and b disconnected. A left lumen valve 5 is located at the valve section 1 of the left lumen a, while a right lumen valve 4 is located at the valve section 1 of the right lumen b. The incisions in both lumen sections are parallel to the catheter body. Both valves are 0.7 cm long and have incisions parallel to the catheter body. The valve section 1 is 6 cm long and is joined to the main body section 2 via one-end injection molding.

[0073] The bidirectional subcutaneous anchor fixing device 8 includes a left and a right side, which can completely overlap. The outer surface of the fixing device is ellipsoidal as a whole, and the width gradually decreases from the middle to the two ends. The length is 0.8 cm, and the maximum single-side width on the left and right sides is 0.4 cm. There are uniform gear-shaped notches on the outer surface of the fixing device, and the notches are 45° to the tube body of the intravenous catheter. The middle of the fixing device is a hollow structure, and the two ends of the fixing device are connected to the catheter. The fixing devices on the left and right sides are on the same horizontal line, and the fixing devices on the left and right sides are centrally symmetrical with the intersection of the catheter axis and the horizontal line as the center point. The notches on the left and right sides of the fixing device are 180°, that is, the notches on the left and right sides are centrally symmetrical with the intersection of the catheter axis and the horizontal line as the center point, and the notches form elliptical rings one by one on the surface of the fixing device; the anchor fixing device is made of silicone rubber with a hardness of 50A and is bonded to the intravenous catheter through a coupling agent.

[0074] The conductive seal 3 is made of conductive polyurethane, the same polyurethane material used in the main body 2, doped with 8wt% graphene oxide. A monitoring guidewire 7 is housed within the right lumen b. This metal, hollow at the center, has an outer diameter of 0.3mm and an inner diameter of 0.15mm. The end is thickened to a diameter of 0.4mm, forming an ECG signal receiving terminal 6. This terminal is 0.5cm long. An optical fiber 13 with a diameter of 0.12mm is housed within the hollow structure. A circular hole with a diameter of 0.28mm is formed on one side of the ECG signal receiving terminal 6, connecting it to the hollow structure. A micro-electromechanical system (MEMS) Fabry-Perot (FPP) pressure sensor 14 with a diameter of 0.26mm is embedded within the hole. This MEMS Fabry-Perot pressure sensor 14 is connected to the optical fiber 13. The other end of the optical fiber 13 extends through an extension tube 10, where it connects to a fiber connector and a data receiving device 12, forming a pressure transmission path with a detection range of 0 to 500 mmHg. The monitoring guidewire 7 is made of silver-tungsten alloy.

[0075] After the catheter is placed in the human body, it is sealed with normal saline and the monitoring guide wire 7 is placed in the catheter to monitor the pressure in the tube in real time. When the pressure value fluctuates greatly, it is judged that the valve is in an unclosed state. The valve is closed by flushing the tube. When the pressure value stabilizes, the valve closes and the pressure inside and outside the tube is balanced. The value at this time is the intravascular pressure.

[0076] After testing, the prepared catheter passed the 350psi injection test and the valve withdrawal test.

[0077] Example 2

[0078] A multifunctional integrated central venous catheter, which is otherwise the same as Example 1, except that: in step 1(2), the molar ratio of IPDI, PBA, and BDO is 3:1:1; in step 2, the molar ratio of IPDI, PBA, and BDO is 3:0.5:1.

[0079] After testing, the prepared catheter passed the 350psi injection test and the valve withdrawal test.

[0080] Example 3

[0081] A multifunctional integrated central venous catheter, which is otherwise the same as Example 1, except that: in step 1(2), the molar ratio of IPDI, PBA, and BDO is 3:1:1.2; in step 2, the molar ratio of IPDI, PBA, and BDO is 3:0.8:0.8.

[0082] After testing, the prepared catheter passed the 350psi injection test and the valve withdrawal test.

[0083] Example 4

[0084] A multifunctional integrated central venous catheter is otherwise the same as in Example 1, except that: in step 3, the lengths of the left luminal valve 5 and the right luminal valve 4 are both 0.5 cm; and the length of the valve segment 1 is 3 cm.

[0085] After testing, the prepared catheter passed the 350psi injection test and the valve withdrawal test.

[0086] Example 5

[0087] A multifunctional integrated central venous catheter is otherwise the same as in Example 1, except that: in step 3, the lengths of the left luminal valve 5 and the right luminal valve 4 are both 0.8 cm; and the length of the valve segment 1 is 8 cm.

[0088] After testing, the prepared catheter passed the 350psi injection test and the valve withdrawal test.

[0089] Example 6

[0090] A multifunctional integrated central venous catheter is the same as Example 1 except that: in step 3, the bidirectional subcutaneous anchor fixing device 8 is 0.5 cm long, the maximum width of the left and right sides is 0.3 cm, and the hardness is 40A.

[0091] Example 7

[0092] A multifunctional integrated central venous catheter is the same as Example 1 except that: in step 3, the bidirectional subcutaneous anchor fixing device 8 is 1 cm long, the maximum width of the left and right sides is 0.5 cm, and the hardness is 60A.

[0093] Example 8

[0094] A multifunctional integrated central venous catheter is the same as Example 1 except that: in step 3, the conductive polyurethane material is made by doping 5wt% of graphene oxide on the basis of the polyurethane material used in the main section 2, and the monitoring guide wire 7 is a silver-copper alloy.

[0095] Example 9

[0096] A multifunctional integrated central venous catheter is the same as Example 1 except that: in step 3, the conductive polyurethane material is made by doping 10wt% of graphene oxide on the basis of the polyurethane material used in the main section 2, and the monitoring guide wire 7 is a silver-iron alloy.

[0097] Comparative Example 1

[0098] A multifunctional integrated central venous catheter, which is otherwise the same as Example 1, except that: in step 1(2), the molar ratio of IPDI, PBA, and BDO is 3:1:0.5; in step 2, the molar ratio of IPDI, PBA, and BDO is 3:0.4:1.2.

[0099] After testing, it was found that the tube body of the prepared catheter bulged and ruptured during the 350psi injection test, and the valve did not withdraw during the valve withdrawal test.

[0100] Comparative Example 2

[0101] A multifunctional integrated central venous catheter, which is otherwise the same as Example 1, except that: in step 1(2), the molar ratio of IPDI, PBA, and BDO is 3:1:1.5; in step 2, the molar ratio of IPDI, PBA, and BDO is 3:1:0.5.

[0102] After testing, the 350psi injection test of the prepared catheter showed that the tube body bulged, but the valve retraction test was qualified.

[0103] Comparative Example 3

[0104] A multifunctional integrated central venous catheter is otherwise the same as in Example 1, except that: in step 3, the lengths of the left luminal valve 5 and the right luminal valve 4 are both 0.3 cm; and the length of the valve segment 1 is 4 cm.

[0105] After testing, the 350psi injection test tube of the prepared catheter bulged and ruptured, and the valve retraction test did not result in retraction.

[0106] Comparative Example 4

[0107] A multifunctional integrated central venous catheter is otherwise the same as in Example 1, except that: in step 3, the lengths of the left luminal valve 5 and the right luminal valve 4 are both 1 cm; and the length of the valve segment 1 is 10 cm.

[0108] After testing, the prepared catheter passed the 350psi injection test and the valve retraction test showed reflux.

[0109] Comparative Example 5

[0110] A multifunctional integrated central venous catheter is the same as Example 1 except that: in step 3, the length of the bidirectional subcutaneous anchor fixing device 8 is 2 cm, the maximum width of the left and right sides is 0.8 cm, and the hardness is 80A.

[0111] Comparative Example 6

[0112] A multifunctional integrated central venous catheter is the same as Example 1 except that: in step 3, the length of the bidirectional subcutaneous anchor fixing device 8 is 0.3 cm, the maximum width of the left and right sides is 0.2 cm, and the hardness is 30A.

[0113] Comparative Example 7

[0114] A multifunctional integrated central venous catheter is the same as Example 1 except that: in step 3, the conductive polyurethane material is made by doping 15wt% of graphene oxide on the basis of the polyurethane material used in the main section 2, and the monitoring guide wire 7 is stainless steel.

[0115] Due to the large amount of graphene oxide doping, it is difficult to shape when preparing polyurethane heads and cannot be tested.

[0116] Comparative Example 8

[0117] A multifunctional integrated central venous catheter is the same as Example 1 except that: in step 3, the conductive polyurethane material is made by doping 3wt% of graphene oxide on the basis of the polyurethane material used in the main section 2, and the monitoring guide wire 7 is nickel-titanium alloy.

[0118] Comparative Example 9

[0119] A multifunctional integrated central venous catheter is the same as Example 1 except that: in step 3, the entire body of the venous catheter is made of the material of the main body segment 2, and the material of the valve segment 1 is not used.

[0120] After testing, it was found that the prepared catheter had tube bulging during the 350psi injection test, and the valve aspiration test was difficult to inject and did not aspirate.

[0121] Comparative Example 10

[0122] A multifunctional integrated central venous catheter is the same as Example 1 except that: in step 3, the entire body of the venous catheter is made of the material of the valve segment 1, and the material of the main body segment 2 is not used.

[0123] After testing, the prepared catheter was found to have bulging and rupture of the tube body during the 350psi injection test, and severe regurgitation during the valve withdrawal test.

[0124] Comparative Example 11

[0125] A multifunctional integrated central venous catheter is the same as Example 1 except that: in step 3, no monitoring guidewire 7 is placed in the right lumen b.

[0126] After the catheter is inserted into the human body, normal saline is used to seal the tube. The closure status of the catheter valve needs to be judged by whether blood refluxes after injection and withdrawal; the electrocardiogram signal needs to be monitored separately through an electrocardiogram monitor; the blood pressure needs to be tested separately through a sphygmomanometer or blood pressure meter, and real-time monitoring cannot be achieved.

[0127] Test methods and steps:

[0128] 1. Mechanical testing: The hardness of the prepared polyurethane was tested using a Shore hardness tester, and the tensile strength, tear strength, elongation at break and 300% strain of the prepared polyurethane were tested using a universal testing machine.

[0129] 2. High-pressure resistance test: The high-pressure resistance of the catheter is tested using a flow and pressure tester for catheter dynamic injection. Normal saline is injected at a flow rate of 10 mL / sec, and the water flows out from the valve. When the pressure reaches 350 psi, the catheter body is not ruptured or bulged. After five tests using the same method, the catheter body is normal and the valve retraction is normal, which is considered qualified.

[0130] 3. Valve withdrawal test: Twist the valve of the catheter three times, connect the front end of the syringe to the central venous catheter, flush 3 mL of sterile water for injection into the tube, withdraw and inject, and repeat this operation three times; the test is qualified if the injection and withdrawal are smooth; keep the catheter tip immersed in the bottom of a beaker 10 cm from the liquid surface, withdraw and inject the catheter until the catheter is filled with water, withdraw the syringe and place this end of the catheter on the edge of the table, observe the liquid reflux, if the liquid does not seep out, it is qualified.

[0131] 4. Heparin grafting amount test: The determination of heparin content mainly adopts the Smith method, that is, the toluidine blue method. Negatively charged heparin and positively charged toluidine blue can form an ionic bond complex in an aqueous solution, while reducing the concentration of toluidine blue in the solution. The ultraviolet absorption peak of toluidine blue is at 625nm, and the content of heparin grafted on the surface of the material can be indirectly obtained by reducing the absorbance of the solution. Using the test of ultraviolet visible spectrophotometer, the linear equation obtained after linear fitting of the data is: Y = 0.60334-0.05994X (R = 0.996). After substituting the absorbance value of heparin into the calculation, the concentration of heparin is obtained. The high or low heparin concentration reflects the size of the grafting density.

[0132] 5. Conductivity test: Use a resistivity meter to test, connect the conductive head 3 and the ECG signal receiving terminal 6, and test the overall resistivity. It is qualified if it is less than 1.2×103Ω / cm.

[0133] 6. Anchor point rebound test: A catheter with a bidirectional subcutaneous anchor fixture 8 is implanted in the subcutaneous tissue of a New Zealand white rabbit. The fixture is clamped with tweezers and compressed and depressed. The test is considered acceptable if the catheter rebounds after implantation without being affected by the catheter. The catheter is considered acceptable if it cannot be easily pulled out with an external force of 5N.

[0134] Test results

[0135] 1. Mechanical parameter test:

[0136] Table 1

[0137] 2. Heparin grafting amount test:

[0138] Table 2

[0139] Test results show that the large volume of POSS on the chain segments restricts their movement, significantly improving the mechanical properties of the polyurethane material. Furthermore, during the polyurethane synthesis process, the prepolymer ratio also affects the material's performance: a higher polyester ratio results in stronger mechanical properties. Similarly, a higher chain extender ratio also enhances mechanical properties. However, the chain extension process consumes isocyanate groups, converting the end groups into hydroxyl groups, which affects the grafting efficiency of the heparinized POSS. Therefore, synthesizing the molecular segments in the appropriate ratio can ensure both mechanical properties and the grafting efficiency of the heparinized POSS.

[0140] 3. Functional testing:

[0141] Table 3

[0142] Test results show that the mechanical strength of the tube must reach a certain level to meet the requirements of high-pressure injection. At the same time, the valve section must maintain smooth flow during injection, otherwise it will block the tube and cause rupture during high-pressure injection. The withdrawal function of the multidirectional valve is related to the hardness of the valve segment 1 material, the length of the valve segment 1, and the valve length. An overly stiff valve will cause difficulty in opening and closing, while a valve segment 1 that is too short will also affect the opening and closing of the valve. A valve that is too short will make injection and withdrawal difficult, while an excessively long valve length can cause the withdrawn fluid to flow back.

[0143] Table 4

[0144] The function of the bidirectional subcutaneous anchor fixing device 8 is related to the hardness and volume of the material. When the material is too soft, the notch part is too soft and cannot be fixed in the subcutaneous tissue. When it is too hard, it will squeeze the catheter, causing the catheter to close and become blocked, affecting its use.

Claims

1. A multifunctional integrated central venous catheter, the tube body is divided into a main body section and a valve section, the valve section is provided with a multidirectional valve, the main body section is made of an anticoagulant, high-pressure resistant polyurethane material, the synthesis method of the material is: isophorone diisocyanate and polybutylene adipate diol are used to synthesize a prepolymer, the chain is extended via 1,4-butanediol, and then heparin and cage oligomeric silsesquioxane are chemically grafted to form heparinized cage oligomeric silsesquioxane to end-cap the synthesized chain segment; the main body section is provided with a bidirectional subcutaneous anchor fixing device, which is placed subcutaneously in a bidirectional fixed catheter during catheterization; the multifunctional integrated central venous catheter is provided with a bidirectional subcutaneous anchor fixing device, which is placed subcutaneously in a bidirectional fixed catheter during catheterization; the multifunctional integrated central venous catheter is provided with a bidirectional subcutaneous anchor fixing device, and the bidirectional fixed catheter ... The cardiac venous catheter is a double-lumen catheter, including a left lumen and a right lumen; the catheter head is a conductive head. The left lumen is used for injecting drugs and withdrawing blood, and the right lumen has a removable monitoring guidewire. The end of the monitoring guidewire is the ECG signal receiving end. When in use, the ECG signal receiving end is connected to the conductive head and connected to the data receiving device through the monitoring guidewire; the center of the monitoring guidewire is a hollow structure with a built-in optical fiber. The ECG signal receiving end is embedded with a micro-electromechanical system Fabry-Perot cavity pressure sensor and connected to the optical fiber. The other end of the optical fiber extends out of the tube and is connected to the optical fiber connector, which is connected to the data receiving device to form a pressure conduction pathway.

2. According to the multifunctional integrated central venous catheter according to claim 1, the valve segment is provided with a three-way valve.

3. The multifunctional integrated central venous catheter according to claim 1 or 2, wherein the preparation method of the anticoagulant and high-pressure resistant polyurethane material comprises the following steps: (1) Preparation of heparinized cage oligomeric silsesquioxane: Sodium heparin, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and N-hydroxysuccinimide were added to a round-bottom flask, and a sodium citrate buffer solution with a pH of 4.8 was added to make the sodium heparin concentration 1 g / L, and the mixture was reacted at 4°C for 24 h; then octaamino cage oligomeric silsesquioxane was dissolved in methanol at a concentration of 2 g / L, and the mixture was put into a round-bottom flask, and the mixture was reacted at 40°C for 24 h; the mass ratio of sodium heparin, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, N-hydroxysuccinimide, and octaamino cage oligomeric silsesquioxane was 3:3:3:

2. After the reaction was completed, the mixture was fully shaken and washed at room temperature, and dried in a vacuum drying oven; (2) Preparation of main segment polyurethane by prepolymer method: under N2 protection, polybutylene adipate diol was added to a dry three-necked flask equipped with a mechanical stirrer, and the mixture was heated at 120°C for 2 h under vacuum to remove moisture. Isophorone diisocyanate and dibutyltin dilaurate were added to the flask equipped with a stirrer, and prepolymerized at 80°C for 3 h to obtain a prepolymer with an isocyanate terminal group. 1,4-butanediol was added, and the reaction was carried out at 60°C for 0.5 h. The mixture was cooled to room temperature. The molar ratio of the added materials was isophorone diisocyanate:polybutylene adipate diol:1,4-butanediol=3:1:(1-1.2). The added dibutyltin dilaurate was 0.05 wt% of the total amount of the added materials. (3) Functionalization of the main segment material: 5 wt % of tetrahydrofuran was added to the main segment polyurethane prepared in step (2) to reduce the viscosity, and the heparinized cage-type oligomeric silsesquioxane prepared in step (1) was added, with the molar ratio of isophorone diisocyanate to heparinized cage-type oligomeric silsesquioxane being 1:0.

05. The mixture was stirred at 60° C. for 1 h, then poured into a polytetrafluoroethylene mold, dried in a forced air drying oven for 24 h, and then transferred to a vacuum drying oven for drying for 12 h to obtain a main segment heparinized high-pressure resistant polyurethane elastomer material.

4. The multifunctional integrated central venous catheter according to claim 1 or 2, wherein the method for preparing the valve segment material comprises the following steps: Under N2 protection, polybutylene adipate diol was added to a dry flask equipped with a mechanical stirrer, and the mixture was heated at 120°C for 2 h under vacuum to remove moisture. Isophorone diisocyanate and dibutyltin dilaurate were respectively added to a flask equipped with a stirrer, and prepolymerized at 80°C for 3 h to obtain a prepolymer. 1,4-butanediol was added, and the mixture was reacted at 60°C for 2 h. Then the heating was turned off, trimethylolpropane was added, and the mixture was stirred for 10 min. The mixture was cooled to room temperature, and a molar ratio of isophorone diisocyanate:polybutylene adipate diol:1,4-butanediol=3:(0.5-0.8):(0.8-1) was added. The amount of dibutyltin dilaurate added was 0.15 wt% of the total amount of the added substances. The mixture was then poured into a polytetrafluoroethylene mold, dried in a blast drying oven for 24 h, and then transferred to a vacuum drying oven for drying for 12 h to obtain a valve segment high-pressure resistant polyurethane elastomer material.

5. According to the multifunctional integrated central venous catheter according to claim 1, the left lumen and the right lumen are exactly the same in shape and size, and are not connected to each other; the two lumens are respectively provided with multidirectional valves in the valve sections, and the two valves are of the same length, both parallel to the tube body, and the length is 0.5 to 0.8 cm.

6. The multifunctional integrated central venous catheter according to claim 1 or 2, wherein the valve segment is 3 to 8 cm in length and is joined to the main body segment by coupling agent bonding, welding or one-end injection molding.

7. According to claim 1 or 2, the multifunctional integrated central venous catheter is provided with a bidirectional subcutaneous anchor fixing device in the main body section. The device includes left and right sides, which can completely overlap. The outer surface of the device is ellipsoidal as a whole. The width gradually decreases from the middle to the two ends of the fixing device. The length is 0.5-1.0 cm. The maximum single-side width of the left and right sides is 0.3-0.5 cm. There are uniform gear-shaped notches in the device, and the notches are 45° to the tube body. The middle of the device is a hollow structure. Both ends of the device are connected to the catheter. The left and right devices are on the same horizontal line and are centrally symmetrical with the intersection of the catheter axis and the horizontal line as the center point. The notches on both sides are 180°, and the notches form elliptical rings one by one on the outer surface of the fixing device.

8. The multifunctional integrated central venous catheter according to claim 7, wherein the bidirectional subcutaneous anchor fixing device is made of silicone rubber and / or polyurethane with a hardness of 40 to 60A and is bonded to the catheter by a coupling agent.

9. The multifunctional integrated central venous catheter according to claim 1 or 2, wherein the conductive end cap is made of a conductive polyurethane material, and the conductive polyurethane material is prepared by doping 5-10 wt% of graphene oxide on the basis of the polyurethane material used in the catheter body.

10. According to the multifunctional integrated central venous catheter of claim 1 or 2, the center of the monitoring guidewire is a hollow structure with an outer diameter of 0.3mm, an inner diameter of 0.15mm, and the diameter of the end is thickened to 0.4mm to form an ECG signal receiving end, with a length of 0.5cm; an optical fiber is built in the hollow structure with a diameter of ≤0.12mm; a circular hole with a diameter of 0.28mm is opened on one side of the ECG signal receiving end, which is connected to the hollow structure, and a micro-electromechanical system Fabry-Perot cavity pressure sensor with a diameter of 0.26mm is embedded in the hole, the micro-electromechanical system Fabry-Perot cavity pressure sensor is connected to the optical fiber, and the other end of the optical fiber extends out of the extension tube to connect to the optical fiber connector, which is connected to the data receiving device to form a pressure conduction path, and the detection range is 0-500mmHg; the monitoring guidewire is one or more of silver-tungsten alloy, silver-nickel alloy, and silver-iron alloy.

Citation Information

Patent Citations

  • Preparation method of novel antibiotic anticoagulant polyurethane material

    CN102127204A

  • Central venous catheter having function of indicating position thereof according to electrocardiograph signal

    CN105233392A

  • Preparation method of plant-oil-based polyurethane composites modified by dual-layer cage type silsesquioxane

    CN105860018A

  • Venous catheter provided with double reflux-preventing valves and making method of venous catheter

    CN108355225A

  • Fluorine and silicon-containing polyurethane material with high biostability and preparation method thereof

    CN110066379A